華潤醫藥(03320.HK)旗下華潤雙鶴與美國Ligand合作開發治療新冠肺炎口服小分子藥物
華潤醫藥(03320.HK)旗下子公司華潤雙鶴藥業股份有限公司的創新事業部與美國生物製藥公司Ligand Pharmaceuticals(LGND.US)於10月20日達成一致,雙方共同開發一款治療新型冠狀病毒肺炎COVID-19的口服小分子RNA聚合(酉每)抑制劑藥物。
項目目前處於臨牀前研究階段,將使用Ligand公司的BEPro技術開展研發。BEPro技術是Ligand公司開發的最新一代前藥技術,適用改善核(甘)類抗病毒藥物的口服給藥療效。BEPro技術開發的抗病毒藥物具有良好的口服生物利用度和提高肺部藥物濃度等特點,對於開發小分子口服新冠治療藥物具有潛在的臨牀治療價值。
未來,華潤雙鶴將有權獲得此藥物在亞洲主要區域的獨家開發和商業化權利。這是華潤雙鶴創新事業部自年初成立以來第二個跨境創新藥項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.